AMGN vs CADL: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AMGN is the larger of the two ($237.84B market cap): the incumbent the market prices for continued execution (17.53x forward earnings, beta 0.42). CADL is the smaller challenger ($400.47M), still expected to post a loss next year: more room to run, but more to prove. If you believe the upside is worth bigger swings, AMGN fits (beta 0.42). If you want the steadier ride, CADL fits (beta -0.29).
AMGN vs CADL: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMGN | CADL | What it tells you |
|---|---|---|---|
| Market cap | $237.84B | $400.47M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 17.53 | -3.56 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.42 | -0.29 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 74% of range | 8% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 16.57 | 3.04 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AMGN and CADL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and CADL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and CADL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Amgen (AMGN) do?
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.
What does Candel Therapeutics (CADL) do?
Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it. Its lead drug, aglatimagene besadenovec (CAN-2409), is an adenovirus carrying a gene that, paired with the oral antiviral valacyclovir, kills tumor cells and releases tumor antigens. A second platform uses a modified herpes virus, linoserpaturev (CAN-3110), now in a Phase 1b trial in recurrent high-grade glioma. Candel sells nothing yet, so every dollar of spending comes from equity and debt.
AMGN vs CADL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
- CADL drivers: The prostate cancer filing in mid-2027; Manufacturing readiness.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For CADL, the main risk is regulatory.
AMGN or CADL: which should you pick?
If the story you believe is AMGN's (Rare disease and Horizon assets), AMGN is the more direct way to own it; if it is CADL's (The prostate cancer filing in mid-2027), CADL is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMGN and CADL guides.
AMGN vs CADL: the full fundamentals
AMGN. As of November 20, 2026, Amgen trades at about 25x trailing GAAP earnings and about 17.5x forward earnings, with EV/EBITDA near 16x, a higher multiple than early 2026 after the shares gained about a third. The dividend yield is about 2.3%. The next report is expected around February 2, 2027, with consensus for the December quarter of adjusted EPS near $5.61 on about $10.48 billion of revenue; the 29 analysts covering the stock rate it a Hold on average, with a mean target of about $436, close to the current price.
CADL. With no sales, Candel is valued on its pipeline. At about $5.11 per share on November 20, 2026, the market cap is about $401M and enterprise value about $250M after netting ~$203M of cash against ~$50M of debt. That is the price the market puts on a drug with positive Phase 3 prostate data, a Phase 3 lung trial just started and an early glioma program. Analysts' average target was ~$22 before the delay and is about ~$17.67 across nine analysts after cuts from Stifel (to $19) and BofA (to $15), which shows how much of the gap depends on approval timing and dilution. A clean filing in mid-2027 or a further slip would likely move this valuation more than any quarterly loss figure.
Headline figures (approximate, November 2026): AMGN shows revenue (ttm) ~$38.9 billion, revenue growth (q3 2026, yoy) ~8.5%, operating margin ~34%, net income (ttm) ~$9.4 billion; CADL shows revenue (ttm) ~$0; no approved products, net loss ~$21.9M in Q3 2026 (EPS about -$0.28 vs ~-$0.31 expected); ~$69.6M for the first nine months, operating expenses ~$23.0M in Q3 2026, up from ~$13.2M a year earlier, cash (sept 30, 2026) ~$203M; runway guided into Q2 2028.
The bottom line: AMGN vs CADL
AMGN and CADL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AMGN and CADL exposure against your real portfolio. It is not an investment adviser.
Wondering how AMGN or CADL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Amgen
Ask Walnut's AI anything about AMGN and see how it fits what you own.
FAQ
What is the difference between AMGN and CADL?
+
Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Candel Therapeutics is a Needham, Massachusetts biotech that builds viral immunotherapies: modified viruses injected straight into a tumor to make the immune system see it. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMGN or CADL the better stock?
+
Neither is universally better. AMGN is the larger incumbent; CADL is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMGN or CADL?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMGN and CADL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMGN vs CADL?
+
AMGN: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including MariTide and its other obesity programs, can fail in late-stage trials or face regulatory setbacks. Newer franchises face their own competition, such as Viridian's Lumvoa against Tepezza. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition left Amgen with about $54 billion of total debt against about $13 billion of cash as of September 30, 2026. After a 34% year-to-date gain the share price of about $440 sits near the ~$436 average analyst target (Mizuho's target is $388 with a Neutral rating), and consensus expects about 8% EPS growth in 2026 and 6.5% in 2027, so the valuation already assumes steady execution. Litigation, manufacturing, and safety risks are inherent to the industry. CADL: The main risk is regulatory. The BLA has already moved once, from late 2026 to mid-2027, and the company says the timing still depends on FDA discussions, so another delay is possible. The FDA could also question the trial's endpoint, the size of the benefit, or the comparison with current care, which in intermediate-risk patients often adds short-course hormone therapy to radiation. Manufacturing is a second risk: viral gene therapies have drawn FDA complete response letters over CMC issues, and assay work is the cause of the current delay. Financing is a third. Cash lasts into Q2 2028, about when an approval could come, so a further slip probably means raising money at a depressed share price; the Trinity loan's later tranches depend on milestones. Lung cancer is a fourth: AURORA is a large, costly trial and a Phase 2a survival figure from a single-arm study often shrinks in randomized testing. Short interest was ~17% of shares outstanding before the drop, which can make the stock move sharply in both directions. With no revenue, the share price has no earnings floor.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMGN or CADL; figures are approximate and dated (as of November 2026). Verify current data before investing.